Hematologic Diseases
170
20
27
93
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Published Results
23 trials with published results (14%)
Research Maturity
93 completed trials (55% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.9%
10 terminated out of 170 trials
90.3%
+3.8% vs benchmark
14%
23 trials in Phase 3/4
25%
23 of 93 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 93 completed trials
Clinical Trials (170)
Data Collection of Standard Care and Evaluation of NHLBI Patients and Donors
Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
Gulf Long-Term Follow-Up Study
Immersive Virtual Reality Applied to Therapeutic Physical Exercise in Cellular Therapy
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
The Impact of the Practice of Touch-massage on the Anxiety of Patients With Hematological Disorders Hospitalized in a Protective Environment, a Randomized, Controlled Study
Pacritinib With Aza for Upfront Myelodysplastic Syndrome
The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease
Bleeding Events Before vs After Lowering Departmental Platelet Transfusion Trigger
Autologous Testicular Tissue Transplantation
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation
A Long-term Follow-up Study in Participants Who Received CTX001
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Clonal Hematopoiesis of Immunological Significance
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants
Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes